Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell ...

Arcellx (ACLX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

REDWOOD CITY, Calif., November 05, 2024--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with ...

Arcellx (NASDAQ:ACLX – Free Report) had its price target raised by Piper Sandler from $91.00 to $115.00 in a report issued on ...

Leerink Partners analyst Daina Graybosch has maintained their bullish stance on ACLX stock, giving a Buy rating on November 8. Daina ...

Truist Financial analyst Asthika Goonewardene reiterated a Buy rating on Arcellx Inc (ACLX – Research Report) today and set a price target of $136.00. The company’s shares closed yesterday at $106.53.

Arcellx, Inc. (ACLX) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $0.81 per share a year ago. These figures are ...

Arcellx (NASDAQ:ACLX – Free Report) had its price objective boosted by Bank of America from $84.00 to $100.00 in a research ...

Baron Health Care Fund highlighted stocks like Arcellx, Inc. (NASDAQ:ACLX) in its Q3 2024 investor letter. Headquartered in Redwood City, California, Arcellx, Inc. (NASDAQ:ACLX) engages in the ...

Arcellx (ACLX) announced an update for its Phase 3 iMMagine-3 study and plans to present Phase 1 and 2 data for anito-cel in ...

Arcellx, Inc. (ACLX) shares rallied 6.7% in the last trading session to close at $92.98. This move can be attributable to notable volume with a higher number of shares being traded than in a ...